Urocortin

What is Urocortin?

Urocortin is the umbrella name for a family of three corticotropin-releasing-factor (CRF) paralogs in mammals — urocortin 1 (Ucn1), urocortin 2 (Ucn2, also called stresscopin-related peptide), and urocortin 3 (Ucn3, also called stresscopin) — each a 38-40 amino acid peptide encoded by a separate gene. Urocortin 1 was identified in 1995 by Joan Vaughan, Wylie Vale, and colleagues at the Salk Institute, who cloned it from rat brain and showed it was related to fish urotensin I and to mammalian corticotropin-releasing factor (CRF/CRH); the founding paper appeared in Nature. Urocortin 2 and urocortin 3 were described in 2001 by two groups working in parallel: Reyes, Lewis, and Vaughan at the Salk Institute (PNAS papers), and Hsu and Hsueh at Stanford, who named them stresscopin-related peptide and stresscopin in their Nature Medicine paper. The three peptides bind two G-protein-coupled CRH receptors with very different selectivity profiles: urocortin 1 binds both CRH-R1 and CRH-R2 with comparably high affinity (it is in fact a more potent agonist at CRH-R2 than CRF itself), while urocortin 2 and urocortin 3 are highly selective for CRH-R2 and have essentially no activity at CRH-R1. This receptor-selectivity story is what makes the urocortin family pharmacologically interesting — it offered, for the first time, endogenous ligands that could dissect the two CRH receptors functionally. Anatomically, urocortin 1 is concentrated in the Edinger-Westphal nucleus, lateral superior olive, and supraoptic nucleus; urocortin 2 is found in hypothalamic paraventricular and supraoptic nuclei, locus coeruleus, and skeletal muscle; urocortin 3 is most abundant in the median preoptic nucleus, perifornical area, and pancreatic beta cells. Functionally, urocortins modulate the hypothalamic-pituitary-adrenal stress axis, cardiovascular performance (potent positive-inotropic and vasodilator actions, with elevated circulating urocortin in human heart failure), appetite (acute administration is anorectic, with effects shifting over time), anxiety-like behavior, and pancreatic glucose homeostasis. Urocortin itself is not an approved therapy — clinical interest has centered on intravenous urocortin 2 and urocortin 3 infusion in heart failure (developed by Mark Davis, Mark Richards, and the Christchurch Heart Institute group in New Zealand) and on small-molecule CRH-R1 antagonists (verucerfont, pexacerfont) for stress-related psychiatric conditions.

What Urocortin Is Investigated For

Urocortins are an endogenous-biology and drug-target topic, not consumer peptides. The most translationally advanced thread is cardiovascular: urocortin 1, urocortin 2, and urocortin 3 all produce striking positive-inotropic and vasodilator effects in animal heart-failure models and in early human studies, and Mark Davis, Mark Richards, and colleagues at the Christchurch Heart Institute in New Zealand carried out IV-infusion studies of all three urocortins in patients with stable congestive heart failure during the mid-2000s. The findings — improved cardiac output, reduced systemic vascular resistance, suppression of plasma aldosterone and endothelin — were promising enough to attract industry interest, but a definitive Phase 2/3 program in heart failure has not been executed at scale, and AAV-delivered urocortin-2 gene therapy for heart failure has remained in preclinical and early translational development (Hammond and colleagues at UC San Diego). The second thread is stress and anxiety: CRF-family receptor pharmacology has driven a long line of small-molecule CRH-R1 antagonist programs (pexacerfont, verucerfont, emicerfont, others) tested in depression, anxiety, irritable bowel syndrome, and alcohol use disorder. Most of these programs have produced disappointing or mixed clinical results despite robust animal data, and the verucerfont alcohol-craving trial (Schwandt et al., 2016) is a representative cautionary example. The third thread is metabolic: urocortin 3 is highly expressed in pancreatic beta cells and serves as a marker of beta-cell maturity, with potential implications for stem-cell-derived beta-cell replacement therapy. As of 2026, no urocortin or CRH-receptor-targeted drug has reached approval for any indication; the family remains a credible but unfulfilled drug-discovery target.

History & Discovery

Urocortin 1 was identified in 1995 by Joan Vaughan, Cynthia Donaldson, Jackson Bittencourt, Marilyn Perrin, Kathy Lewis, Steve Sutton, Ron Chan, Andrew Turnbull, David Lovejoy, Jean Rivier, Catherine Rivier, Paul Sawchenko, and Wylie Vale at the Salk Institute. Working in Vale's laboratory — the same group that had isolated CRF in 1981 — the team cloned a novel rat brain peptide whose sequence was clearly homologous to fish urotensin I and to mammalian CRH/CRF. The November 1995 Nature paper named the peptide 'urocortin' to reflect this dual lineage (urotensin + corticotropin-releasing factor) and reported its high-affinity binding at both CRH receptors and its distinctive anatomical distribution in the Edinger-Westphal nucleus and lateral superior olive. For the next six years, urocortin 1 was the only known mammalian member of the family. Then, in 2001, two laboratories independently identified two additional CRF-family peptides. Teresa Reyes, Kathy Lewis, Marilyn Perrin, Joan Vaughan, Paul Sawchenko, Wylie Vale, and colleagues at the Salk Institute reported urocortin 2 in PNAS in February 2001, naming it for its sequence homology with urocortin 1 and characterizing its high CRH-R2 selectivity. Sheau-Yu Hsu and Aaron Hsueh at Stanford, working from a bioinformatics search of expressed-sequence-tag databases, simultaneously identified the same two peptides and named them stresscopin-related peptide (urocortin 2) and stresscopin (urocortin 3) in their May 2001 Nature Medicine paper. The Salk group then reported urocortin 3 in PNAS in June 2001 (Lewis et al.), completing the description of the three-member family. The dual nomenclature persists: 'urocortin 2/urocortin 3' is more common in the cardiovascular and neuroscience literature, 'stresscopin-related peptide/stresscopin' more common in stress-physiology contexts. The cardiovascular translational story emerged from the Christchurch Heart Institute in New Zealand, where Mark Davis, Mark Richards, Tim Yandle, Chris Pemberton, John Lainchbury, Miriam Rademaker, Chris Charles, and colleagues performed a series of urocortin infusion studies in experimental and human heart failure during the early-to-mid 2000s. The 2005 Clinical Science paper on urocortin 1 in stable heart-failure patients, the 2006 European Heart Journal paper on urocortin 3 in experimental ovine heart failure, and the 2007 European Heart Journal paper on urocortin 2 in human heart failure together built the case for urocortins as a candidate IV inotrope-vasodilator class. The hemodynamic profile — increased cardiac output without increased oxygen demand, vasodilation without reflex tachycardia, and suppression of aldosterone and endothelin — was distinctive enough to attract industry interest. Larger Phase 2/3 development did not materialize, although AAV8-urocortin 2 gene therapy programs (Hammond, Lai, Gao, and colleagues at UC San Diego) have advanced the cardiovascular concept into a delivery format that is more pragmatic for chronic heart failure. The stress-axis and anxiety pharmacology developed in parallel. Urocortin 1's appetite-suppressing effect in rats was established by Spina, Merlo-Pich, Chan, Basso, Rivier, Vale, and Koob (Science 1996). The CRH-R1 antagonist drug-discovery program — driven by the rationale that CRH-R1 mediates the anxiogenic and ACTH-releasing arm of the stress response — produced a long line of candidates including pexacerfont, verucerfont, emicerfont, and others. Most of these candidates produced strong receptor occupancy and pharmacodynamic effects on neuroendocrine readouts but failed to deliver convincing efficacy in anxiety, depression, IBS, or alcohol use disorder. The 2016 Schwandt et al. verucerfont trial in alcohol-dependent women is a representative case: the drug normalized HPA-axis stress responses but failed to reduce craving. The discrepancy between strong preclinical and weak clinical efficacy for CRH-R1 antagonism remains a foundational puzzle in stress-system pharmacology. A newer strand of urocortin biology centers on metabolism. Urocortin 3 is highly expressed in mature pancreatic beta cells and is co-secreted with insulin on glucose stimulation; Mark Huising, Talitha van der Meulen, and colleagues established it as a marker of beta-cell maturation and an autocrine/paracrine regulator of islet function. In stem-cell-derived beta-cell replacement therapy programs (for type 1 diabetes), urocortin 3 expression has become a standard marker of full functional maturity. As of 2026, the urocortin family remains a credible drug-discovery target with no approved drug — a 30-year-old story whose final chapter has not been written.

How It Works

Urocortin is a family of three signaling proteins (urocortin 1, 2, and 3) that the body makes to talk to two receptors called CRH-R1 and CRH-R2. These receptors are the same ones that the stress hormone CRH uses to trigger cortisol release. But urocortins do more than stress. In the heart, they make the muscle pump harder while also relaxing blood vessels — a combination that is unusually attractive for treating heart failure. In the brain, they shape anxiety and feeding behavior. In the pancreas, urocortin 3 is made and released by insulin-producing beta cells and helps fine-tune blood sugar control. Researchers have spent decades trying to turn this biology into approved drugs — IV urocortin for heart failure, small-molecule blockers for anxiety and depression — but no urocortin-based therapy has yet crossed the regulatory finish line.

Urocortin 1 (Ucn1) is a 40-amino-acid peptide identified by Joan Vaughan and Wylie Vale at the Salk Institute in 1995 (Nature paper), cloned from rat brain and named for its homology to fish urotensin I and to mammalian CRH/CRF. Urocortin 2 (Ucn2, stresscopin-related peptide) is a 38-amino-acid peptide described by Reyes, Lewis, Perrin, Kunitake, Vaughan, and colleagues in PNAS 2001. Urocortin 3 (Ucn3, stresscopin) is a 38-amino-acid peptide described in parallel by Lewis et al. (PNAS 2001) and by Hsu and Hsueh (Nature Medicine 2001). All three are encoded by separate genes (UCN, UCN2, UCN3 in humans). The three peptides bind two GPCRs of the class B (secretin-like) family: CRH-R1 (CRHR1) and CRH-R2 (CRHR2). Receptor binding is sharply differentiated. Urocortin 1 binds CRH-R1 and CRH-R2 with comparably high affinity and is in fact a more potent CRH-R2 agonist than CRF itself, making it the most pharmacologically promiscuous member of the family. Urocortin 2 and urocortin 3 are highly selective for CRH-R2, with urocortin 3 the most CRH-R2-selective ligand of the three. CRH-R1 couples primarily to Gs and activates adenylate cyclase to raise intracellular cAMP, with downstream PKA and CREB signaling — this is the canonical pathway for ACTH release from anterior pituitary corticotropes. CRH-R2 couples to Gs as well, with similar cAMP-PKA signaling but in different anatomical compartments (cardiac myocytes, vascular smooth muscle, hypothalamic and limbic neurons, pancreatic islet cells, skeletal muscle). The two receptors can also engage Gq/PLC and beta-arrestin pathways depending on cellular context. Anatomical distribution of the ligands is non-overlapping. Urocortin 1 is concentrated in the Edinger-Westphal nucleus, the lateral superior olive, and the supraoptic nucleus, with peripheral expression in heart, immune tissues, and some endocrine glands. Urocortin 2 is expressed in hypothalamic paraventricular and arcuate nuclei, the locus coeruleus, skeletal muscle, the heart, and the pituitary. Urocortin 3 is found in the median preoptic nucleus, the perifornical area of the hypothalamus, and prominently in pancreatic beta cells, where it is co-secreted with insulin on glucose stimulation. Functionally, the cardiovascular actions are striking. In experimental heart failure (sheep, rats, dogs) and in human heart-failure patients (Davis, Pemberton, Richards, and colleagues, Christchurch Heart Institute), IV infusion of urocortin 1, urocortin 2, or urocortin 3 produces marked positive inotropy (increased cardiac contractility), positive lusitropy (improved relaxation), systemic and pulmonary vasodilation, and suppression of plasma aldosterone and endothelin — a hemodynamic profile that uniquely combines inotropy with vasodilation without the catecholaminergic burden of dobutamine. Cardioprotective effects of urocortin against ischemia-reperfusion injury, mediated through MAPK-dependent pathways and induction of heat shock proteins, were established by Brar, Latchman, and colleagues in cardiomyocyte and isolated-heart preparations. In the central nervous system, urocortins act through CRH-R1 and CRH-R2 to modulate stress, anxiety, and feeding. Acute central administration of urocortin 1 is anorectic (Spina, Merlo-Pich, and colleagues, Science 1996), with effects distinct from CRF-induced stress feeding. Anxiety-like behavior is shaped by CRH-R1 (predominantly anxiogenic) and CRH-R2 (with more complex, context-dependent effects). The CRH-R1 antagonist class — pexacerfont, verucerfont, emicerfont, and related small molecules — was developed on this rationale, although clinical results have been disappointing. In pancreatic islets, urocortin 3 is a marker of beta-cell maturity and is co-secreted with insulin on glucose stimulation, signaling through CRH-R2 on neighboring delta cells to stimulate somatostatin release as a paracrine brake on further insulin secretion (Huising and van der Meulen). In skeletal muscle and adipose tissue, urocortin 2 acting at CRH-R2 modulates glucose uptake and metabolic flexibility — a target area that remains under exploration.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Urocortin:

• 01Whether IV urocortin 2 or urocortin 3 infusion can deliver durable mortality or hospitalization benefit in acute decompensated heart failure — the Christchurch single-center hemodynamic studies are encouraging but a definitive Phase 3 outcomes trial has not been completed.
• 02Whether AAV8-urocortin 2 gene therapy will achieve adequate efficacy and safety in human chronic heart failure — preclinical data are strong but human translation is in early stages.
• 03Why CRH-R1 antagonists (pexacerfont, verucerfont, emicerfont, others) have repeatedly failed to deliver clinical efficacy in anxiety, depression, IBS, and alcohol use disorder despite robust preclinical rationale — whether the issue is dose, patient stratification, redundancy in stress circuits, or fundamental misalignment of the target.
• 04Whether urocortin 2 acting at CRH-R2 in skeletal muscle is a viable target for metabolic disease — animal data on glucose uptake and insulin sensitivity are intriguing but human translation is minimal.
• 05The functional role of urocortin 3 in pancreatic beta-cell physiology beyond its biomarker status — whether urocortin 3 or CRH-R2 modulators have a role in diabetes therapy.
• 06Whether the dual nomenclature (urocortin 2/3 versus stresscopin-related peptide/stresscopin) will converge on a single name as the field matures — a small but persistent source of confusion in the literature.
• 07The long-term safety profile of chronic urocortin or CRH-receptor pathway modulation in humans, particularly with respect to bone, immune, and cognitive endpoints that are sensitive to glucocorticoid signaling.

Forms & Administration

Urocortins are not formulated or approved as therapeutics in any jurisdiction. Research applications use synthetic urocortin 1, urocortin 2, or urocortin 3 (rat or human sequence) for in vitro receptor binding and signaling assays, ex vivo cardiac and islet preparations, intracerebroventricular or intravenous administration in animal models, and a small number of investigational human IV-infusion studies in heart failure under research protocols at the Christchurch Heart Institute and a few other centers. Urocortin-2-encoding adeno-associated virus (AAV) vectors have been developed as experimental gene therapy for heart failure (Hammond and colleagues at UC San Diego) and are in preclinical and early translational stages. Small-molecule CRH-R1 antagonists in development as research and investigational drugs are not the same molecule class as urocortin itself, although they target the same receptor system. Compounded urocortin from peptide marketplaces has no validated clinical use.

Common Questions

Who Urocortin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for urocortins because no urocortin product has been clinically approved. Theoretical interactions follow from the peptides' known pharmacology. The cardiovascular effects (vasodilation, positive inotropy) overlap mechanistically with nitrates, ACE inhibitors, angiotensin receptor blockers, hydralazine, and milrinone — combinations would risk additive hypotension. Beta-blockers might attenuate the inotropic component but not the vasodilation. Diuretics and aldosterone antagonists target the same neurohormonal axis that urocortins suppress; whether the combination would be additive or redundant is unclear. The HPA-axis effects of urocortin 1 (CRH-R1 engagement, ACTH and cortisol release) could interact with glucocorticoids, ketoconazole, mifepristone, and other agents that modulate adrenal function. Urocortin 3's pancreatic beta-cell signaling raises theoretical interactions with insulin, sulfonylureas, GLP-1 receptor agonists, and DPP-4 inhibitors, although the clinical relevance is unknown. CRH-R1 antagonists in development would be expected to interact with corticosteroids, antidepressants (SSRIs, SNRIs), and benzodiazepines through both pharmacodynamic and CYP-mediated routes; the clinical-trial datasets from the verucerfont and pexacerfont programs are the relevant references rather than urocortin itself. None of these interactions is documented in clinical-care contexts because no urocortin or CRH-receptor drug is approved.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions